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A 50-year-old man with immunoglobulin A type multiple myeloma (MM) was referred to our hospital after bor-
tezomib therapy. He had high alkaline phosphatase and lactate dehydrogenase levels. Computed tomography 
showed osteolytic and osteoblastic bone lesions. Response to salvage chemotherapy was temporary, and he 
developed a right pleural effusion with high adenosine deaminase (ADA) levels. He died from bleeding associated 
with a pelvic bone fracture 9 months later. ADA mRNA expression and ADA secretion of the MM cells from the 
patient were higher than those from myeloma cell lines tested. Clinical relevance of high ADA expression in MM 
cells is warranted.
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Introduction
Multiple myeloma (MM) is characterized by the accumula-
tion of neoplastic plasma cells in the bone marrow which 
 generates multiple bone lesions through enhanced osteo-
clastogenesis and concomitant suppression of osteoblastic 
differentiation from the bone marrow stromal cells. MM is still 
difficult to be cured; therefore, additional novel treatment 
strategies are needed.
Adenosine deaminase (ADA) is an important enzyme in the 
purine metabolism that catalyzes the deamination of both 
adenosine and 2’-deoxyadenosine to inosine and 2’-deoxyinosine, 
respectively [1]. However, limited information is available 
regarding ADA production and its role in MM.
Here, we report a patient with MM exhibiting an aggressive 
clinical course with a pleural infiltration of MM cells expressing 
high levels of ADA.
Case Report
A 50-year-old man presented with general fatigue, appetite 
loss, and pain in shoulders, back, and ribs from December 
20XY. He was diagnosed with MM in March next year. He had 
hypercalcemia, renal insufficiency, and serum immunoglobulin 
A (IgA)-λ type M-protein at 2420 mg/dl with multiple osteo-
lytic and osteoblastic lesions. In addition, 88% of bone 
 marrow cells were occupied by MM cells. After 2 courses 
of bortezomib, dexamethasone, and cyclophosphamide 
 combination therapy, he was referred to our hospital for sub-
sequent treatment. Urinalysis revealed proteinuria, whilst 
 peripheral blood tests showed normocytic anemia, high alka-
line phosphatase (ALP), high lactate dehydrogenase (LDH) and 
IgA level of 608 mg/dl. Bone metabolic markers revealed 
high levels of bone resorption and formation activity (Table 1). 
A chest X-ray scan showed multiple extramedullary tumors 
in both lungs. Computed tomography revealed systemic 
bone lesions. Most notably, osteolytic and osteoblastic lesions 
were intermingled in spinal bones and the sternum (Fig. 1a, 
1b, and 1c). Bone marrow MM cells were immature in appear-
ance with a CD38 (+), CD138 (+), CD19 (–), CD56 (+), CD20 (–), 
CD33 (–), CD49e (–), and MPC-1 (–) phenotypes (Fig. 1d). 
 Fluorescent in situ  hybridization analysis revealed complicated 
karyotypes with deletion of chromosomes 1,13q and 17 
together with (4;14) translocation in the bone marrow cells. 
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Figure 1. Myeloma bone lesions and morphology of myeloma cells. a: Multiple punched out lesions are observed in an X-ray scan of the skull 
(red arrow). b: Osteolytic myeloma bone disease in the right upper arm (red arrow). c: Osteogenic myeloma bone disease in the vertebral 
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Bortezomib, lenalidomide, and dexamethasone combination 
chemotherapy was not effective; however, two salvage courses 
of hyperfractionated cyclophosphamide, vincristine, doxo-
rubicin, and dexamethasone (hyper-CVAD) therapy followed 
by thalidomide monotherapy appeared effective; and the 
 patient achieved a partial response. ALP was lowered to nor-
mal range after  hyper-CVAD therapy; however, LDH and IgA 
levels resumed to increase immediately followed by rapid ex-
pansion of a right pleural effusion. Examination of the pleural 
effusion revealed a high level of ADA (453 U/L) with abun-
dant myeloma cells. Mycobacterium species were not detected 
in the pleural effusion. Computed tomography scans showed 
multiple ex tramedullary expansion of tumors with a bulky 
mass. Com bination chemotherapy of cyclophosphamide, 
doxorubicin,  vincristine, and prednisone was temporarily effec-
tive as subsequent salvage chemotherapy although a tumor 
lysis syndrome emerged. He underwent a talc pleurodesis 
to palliate his respiratory  distress. Salvage chemotherapy 
 regimens of dexamethasone, etoposide, ifosfamide and 
 carboplatin;  fludarabine; dexamethasone, cisplatin, doxorubi-
cin, cyclophosphamide and etoposide were only temporarily 
effective. The patient died from bleeding, resulting from a 
 pelvic bone fracture (Fig. 2), only 13 months after the diag-
nosis and 9 months after the emergence of the pleural effu-
sion. Serum levels of LDH and ADA were found to reflect a 
MM tumor  expansion.
Discussion
Herein, we described an MM patient with poor risk chro-
mosomal abnormality and severe bone lesions who quickly 
developed a right pleural effusion with high ADA mRNA 
expression and secretion from MM cells (Fig. 3). The progres-
sive nature of his condition and his resistance to chemo-
therapy eventually lead to his death.
Pleural effusion in myeloma is not uncommon; Kintzer et al. 
reported that 6% of MM cases develop pleural effusion [2]. 
Most cases of effusion are derived from renal failure, heart 
 failure, hypoalbuminemia, and infection. However, malignant 
pleural effusion only occurs in 1% or less of MM cases, making 
it relatively rare [2]. In our case, the patient developed unilat-
eral pleural effusion with MM cell infiltration and high ADA in 
the supernatant of the effusion. Repeated examination ruled 
out tuberculosis, and we verified in vitro that ADA was pro-
Figure 2. Clinical course. After hyper-CVAD therapy as a salvage therapy, a right pleural effusion with high ADA expressive myeloma cells 
developed. Patient underwent talc pleurodesis to palliate his respiratory symptoms. CHOP, DeVIC and D-PACE salvage chemotherapy 
induced repetitive TLS, however, anti-tumor effect was temporary. The patient died from a pelvic bone fracture after 13 months after 
diagnosis of myeloma.
 Abbreviations: ADA = adenosine deaminase; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; DeVIC = dexamethasone, 
etoposide, ifosfamide and carboplatin; D-PACE = dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide; hyper-CVAD = 
hyperfractionated cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone; IgA = immunoglobulin A; LDH = lactate 
dehydrogenase; TLS = tumor lysis syndrome.
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duced by MM cells in the pleural effusion because both tran-
scriptional and protein levels were much higher than in other 
MM cell lines (Fig. 3). In a clinical setting, ADA is used as a 
diagnostic marker for tuberculous pleuritis, peritonitis, and 
meningitis because ADA protein expression in these effusions 
is known to be positively correlated with tuberculosis [3–5]. 
The role of ADA in MM is unclear, and to date, only 7 patients 
with MM and high ADA expression have been reported [6–8]. 
All of them developed pleural effusion during their treatment. 
Six of seven patients were under sixty-year-old, markedly 
young. The IgD isotype was seen in 3 cases, and the IgG and 
IgA isotypes were in 2 cases respectively. Bone disease and 
monosomy 13 or del(13q) were seen in three cases (Table 2). 
In our case, the ADA level from the effusion was the highest 
among all previously reported cases. Period of their survival 
was reported to be between only a month and 1 year.
ADA is a critical enzyme expressed in all tissues of human 
body that catalyzes the deamination of both adenosine and 
2’-deoxyadenosine to inosine and 2’-deoxyinosine, respec-
tively [1]. ADA is also regarded as an activation marker of 
lymphoid cells, and the absence of ADA results in both intra- 
and extracellular accumulation of adenosine, which leads to 
lymphocyte apoptosis and immune deficiency [9]. High ADA 
expression reflects high purine metabolism activity; therefore, 
ADA is thought to be a probable target for the inhibiting 
 cancer metabolism. A number of ADA inhibitors have been 
synthesized [10], and some are approved for their clinical use, 
including cladribine for hairy cell leukemia and relapsed/
refractory follicular or mantle cell lymphoma as well as 
 pen tostatin for hairy cell leukemia and adult T-cell leukemia. 
 However, ADA inhibitors has not yet been studied in MM.
Adenosine, a substrate of ADA, has drawn considerable 
attention for its association with cancer. Adenosine activates 
the adenosine receptors on the target cell, which generate 
various cellular responses, including immune cell regulation 
and tumor cell proliferation that result in alteration of the 
Table 2. Reported myeloma cases with high ADA expression in the pleural effusion
Ref. Age Gender Type ADA (U/l) Bone disease
Monosomy13 
or del (13q)
Survival after pleural effusion 
appearance (month)
6 49 M IgA-κ 61 ND ND 11
7 58 M IgD 50 ND ND 1
8 53 M IgD-λ 68.4 osteolytic + 3.7
8 53 F IgA-κ 84.2 — ND 0.7
8 53 M IgG-κ 108.5 osteolytic + 0.8
8 67 M IgD-λ 117.8 osteolytic + 15.6
8 48 F IgG-κ 60.6 — – 4.1




Figure 3. Expression of ADA in MM cells. MM cells from his pleural 
effusion were purified with positive selection using CD138 
(Syndecan-1) microbeads and the Miltenyi magnetic cell-sorting 
system (Miltenyi Biotec, Auburn, CA), according to the manufac-
turer’s instructions. The MM cells were then cultured, and total 
RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, 
CA). For reverse transcription–polymerase chain reaction as 
 previously described. The specific primers used were forward 
5’-TTCCTTCCAAGAAGACCATGA-3’, reverse 5’-GGTTTCAGATTCA 
ACCATGC-3’, for human ADA, forward 5’-TGTCTTCACCACCATG 
GAGAAGG-3’ and reverse 5’-GTGGATGCAGGGATGATGTTCTG-3’ 
for human glyceraldehyde-3-phosphate dehydrogenase. MM 
cells were cultured for two days at 1 × 106 cells/ml in RPMI 1640 
medium with 5% fetal bovine serum. The supernatants were 
collected and their ADA levels were measured. All procedures 
involving human specimens were performed with written 
informed consent according to the Declaration of Helsinki, and 
the protocol was approved by the Institutional Review Board for 
human protection in Tokushima University hospital (approval 
No. 240-2). ADA mRNA expression and production of the 
patient’s MM cells from the pleural effusion were significantly 
higher compared to those in peripheral blood mononuclear 
cells (PBMCs) from a healthy donor and MM cell lines tested.
 Abbreviations: ADA = adenosine deaminase; PBMCs = peripheral 
blood mononuclear cells.
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tumor microenvironment [11]. On the other hand, deaminase 
activity also seems to be important in cancer. The adenosine 
deaminase acting on RNA (ADAR) family genes and proteins 
deaminate adenosine to inosine in double-stranded RNA. 
They were discovered through the purification of Xenopus, 
bovine liver, and calf thymus [12–14] . This reaction is 
 commonly referred to as Adenosine-to-Inosine RNA editing, 
a highly conserved mechanism in mammals [15]. ADAR is 
reported to affect various human biochemical activities, such 
as mRNA translation, RNA stability, RNA replication, and RNA 
silencing, which involves hematopoiesis and pluripotency of 
hematopoietic stem cells [16]. Although it is unclear whether 
deamination activity influences on MM progression, we need 
further studies on adenosine or its deamination-related 
pathophysiology and tumor pathophysiology in MM.
Bone disease in our case showed a characteristic feature 
with simultaneous osteoblastic and osteoclastic bone lesions 
when he was referred to our hospital. In humans, osteoblast 
precursor produce adenosine that has a potent stimulatory 
action on IL-6 secretion but an inhibitory action on osteo-
protegerin [17]. In addition, adenosine signaling is reported 
to stimulate human osteoblastogenesis [18] and osteo-
clastogenesis [19]. Therefore, adenosine or ADA activity 
might affect the characteristic phenotype of bone disease 
in our patient.
In summary, we described a patient with MM showing high 
ADA expression with bone disease mixed with osteolytic and 
osteoblastic lesions and unilateral pleural effusion. Because 
the role of ADA in MM pathophysiology and MM bone lesions 
remains unknown, further clinical experiences and laboratory 
investigations are warranted.
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